Experimental Treatment for Neurofibromatosis Type 1 Earns Orphan Drug Designation in the EU
<a href="https://pixabay.com/users/pixel2013/">pixel2013</a> / Pixabay

Experimental Treatment for Neurofibromatosis Type 1 Earns Orphan Drug Designation in the EU

According to a story from BioPortfolio, the biopharmaceutical company SpringWorks Therapeutics, Inc., has recently announced that the European Commission has given the company's investigational drug candidate mirdametinib Orphan Drug designation.…

Continue Reading
Close Menu